Novacyt S.A.:Half Year Results; Double-digit revenue growth; EBITDA profit
Novacyt (ALTERNEXT: ALNOV; AIM: NCYT) ("Novacyt", the "Company" or the "Group"), an international specialist in clinical diagnostics, today announces unaudited results for the six months ended 30 June 2019.
Consolidated unaudited Group revenue of (EURO)7.2m, an increase of 12% (11% CER) compared to the restated revenues for H1 2018 of (EURO)6.4m
Primerdesign revenue increased 8% (7% CER) to (EURO)3.3m
Lab21 revenue increased 17% (16% CER) to (EURO)4.0m as a result of the incremental revenue from the Omega ID acquisition in June 2...